CURRICULUM VITAE

Steven P. LaRosa, M.D.

Address ** ******** ****

South Hamilton, MA 01982

Phone 401-***-****

Email ac74bz@r.postjobfree.com

EDUCATION

Undergraduate Bachelor of Science in Biology, Magna cum laude

Boston College, Boston, Massachusetts, 09/1984-05/1988

Medical School Doctor of Medicine, Alpha Omega Alpha

Boston University School of Medicine

Boston, Massachusetts, 09/1988-05/1992

POSTGRADUATE TRAINING

Residency Internal Medicine, Cleveland Clinic Foundation,

Cleveland, Ohio, 07/01/1992-06/30/1995

Chief Residency Internal Medicine, Cleveland Clinic Foundation,

Cleveland, Ohio, 07/01/1995-06/30/1996

Fellowship Infectious Disease

Massachusetts General Hospital, Boston, Massachusetts, 07/01/1996-06/30/1998

POSTGRADUATE HONORS AND AWARDS

Alpha Epsilon Delta Premedical Honor Society, 1987

College of Arts and Sciences Honors Program, 1988

Alpha Omega Alpha Honor Society, 1992

Chester Keefer Memorial Award (Commencement Award), 1992

Boston VA Medical Center Award in Internal Medicine

(Commencement Award), 1992

Dean’s Teaching Excellence Award, Brown Medical School, 2005

Dean’s Teaching Excellence Award, Brown Medical School, 2006

Brown Infectious Diseases Fellowship Steven M. Opal Teaching Award

2008-2009

Castle Connolly, Regional Top Doctors, Infectious Disease 2009-2018

PROFESSIONAL LICENSES AND BOARD CERTIFICATION

License

(expired) Texas-MD, 2011-to 5/31/2014

License

(expired) Rhode Island – MD, 2004-2011

License

(active) Massachusetts – MD, 1996-1998, 6/20/2012 to present

License

(expired)Indiana – MD, 1999

License

(expired)Ohio – MD, 1993 – 2004

Board Certification

Internal Medicine through Dec 31, 2028

Infectious Disease through Dec 31, 2019

EMPLOYMENT HISTORY

Attending Physician Division of Infectious Disease, Beverly Hospital/Lahey Health, 09/04/2012-present

Medical Director Antimicrobial Stewardship Program, Beverly Hospital/Lahey Health, 09/04/2012-present

Division Director Division of Infectious Disease, Scott and White

Healthcare, 06/27/2011-6/16/2012

Director Ocean State Clinical Coordinating Center,

Rhode Island Hospital, 04/15/2004-05/30/2011

Attending Physician Division of Infectious Diseases, Rhode Island Hospital,

04/15/2004-05/30/2011

Consulting Physician Women & Infants Hospital, 04/15/2004/05/30/2011

Associate Staff Physician Department of Infectious Disease

Cleveland Clinic Foundation, 04/01/2001-03/31/2004

Clinical Research Physician Phase III Trial of recombinant human activated protein C (rhAPC, Xigris™) in severe sepsis (PROWESS Trial), Lilly Research Laboratories, Lilly Corporate Center, 1998-2001

HOSPITAL/UNIVERSITY COMMITTEES

Member System P&T Committee, Lahey Health, 03/15/2016-present

Member Infection Control Committee, Beverly Hospital, 09/01/2012 –present

Member Antibiotic Subcommittee, Beverly Hospital, 09/01/2012-present

Member CME Committee, Beverly Hospital, 09/01/2012-present

Member P&T Committee, Beverly Hospital, 09/01/2012-present

Member Multidisciplinary Peer Review Committee, Beverly Hospital, 09/01/2012-present

Member Hand Hygiene Committee, Scott and White Healthcare 2011-2012

Member Billing Committee, Rhode Island Hospital, 2006-2009

Member Quality Assurance Committee, Department of Medicine,

Rhode Island Hospital, 2005-2009

Member Antimicrobial Subcommittee, Pharmacy and Therapeutics

Committee, Lifespan/Rhode Island Hospital, 2011

Member Infectious Diseases Fellowship Committee, The Warren Alpert

Medical School of Brown University, 2004-2011

Member Xigris™ Guidelines Committee, Cleveland Clinic Foundation, 2001

Member Resident Selection Committee Cleveland Clinic Foundation, 1996

Member Formulary Committee, Cleveland Clinic Foundation, 1996

ACADEMIC APPOINTMENTS

Associate Professor of Medicine

Texas A&M Health Science Center, College of

Medicine, 06/2011-6/2012

Assistant Professor

The Warren Alpert Medical School of Brown

of Medicine

University, 03/2004-05/2011

Clinical Assistant

Penn State University School of Medicine, 03/2001-03/2004

Professor of Medicine

Clinical Assistant

Internal Medicine, Hershey Medical School, 07/1995-06/1996

Clinical Assistant

Ohio State University of Medicine, 07/1995-06/1996

OTHER APPOINTMENTS

Ex-officio Chief Medical Epiphany Biosciences, June 2018 -present

Officer

Ex-officio Chief Medical Hessian Pharmaceuticals, Feb 2018 -present

Officer

Ex-officio Chief Medical Enbiotix, Inc, 2015- May 2016

Officer

Senior Medical Leading Biosciences, Inc., 2015-Jan 2016

Advisor

Associate Medical Director New England Life Care, 2015-present

Member Medical Advisory Board, ExThera Medical, 2011-present

Member Event Adjudication Committee, A Phase 2b, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Safety and Efficacy of Staphylococcus aureus 4-antigen (SA4Ag) in Adults Undergoing Elective Posterior Instrumental Lumbar Spinal Fusion Procedures, 2015-present

Member Data Monitoring Committee, Phase Ib/2a Study – Anti-PD –L1 monoclonal antibody (BMS-936559) for Severe Sepsis, 2015-2018

Member Data Safety Monitoring Board, A Study of IL-7 to Restore Absolute Lymphocyte Counts in Sepsis Patients (IRIS-7-B)- 2015-present

Member Data Safety Monitoring Board, Phase I Study -GEDI-102-ADS, 2008-2010

Co-Chair Clinical Evaluation Committee, ACCESS study, 2007-2010

Member Clinical Evaluation Committee, TFP008 Study, 2004-2007

Member Clinical Evaluation Committee, TFP007 Study, 2005

Chairman Clinical Evaluation Committee, Phase II trial of E5564 in Severe

Sepsis, 2002-2005

Member Clinical Evaluation Committee, BAR03 Phase III Study of PAFase

in Severe Sepsis, 2003

MEMBERSHIP IN SOCIETIES

Member Society of Critical Care Medicine, 1998-present

Member Infectious Disease Society of America, 1996-present

ORIGINAL PUBLICATIONS IN PEER-REVIEWED JOURNALS

1.Gordon S, LaRosa S, Kalmadi S, et al. Should prophylaxis for pneumocystis carinii pneumonia in solid organ transplant ever be discontinued? Clin Infect Dis 1999;28:240-246.

2.Bernard GR, Vincent JL, Laterre PF, LaRosa SP, et al. Efficacy and safety of recombinant human activated protein C for severe sepsis. N Engl J Med 2001;344(10):699-708.

3.LaRosa SP. Sepsis: menu of new approaches replaces one therapy for all. Cleve Clin J Med 2002;69(1):65-73.

4.LaRosa SP. Conflict of interest: Authorship issues predominate. Arch Intern Med 2002; 162.

5.Singh-Behl D, LaRosa SP, Tomecki KJ. Tick-borne infections. Dermatol Clin 2003;21:237-244.

6.Opal SM, Garber GE, LaRosa SP, et al. Systemic host responses in severe sepsis analyzed by causative microorganism and treatment effects of drotrecogin alfa (activated). Clin Infect Dis 2003;37:50-58.

7.Dhainaut JF, Laterre PF, LaRosa SP, et al. The clinical evaluation committee in a large phase 3 trial of drotrecogin alfa (activated) in patients with severe sepsis (PROWESS). Crit Care Med 2003;31:2291-2301.

8.Kalil AC, Coyle SM, Um JY, LaRosa SP, et al. Effects of drotrecogin alfa (activated) in human endotoxemia. Shock 2004;21(3):222-229.

9.LaRosa SP, Tomecki KJ. Antibiotics: What’s new. Cutis 2004;73(1):10-14.

10.LaRosa SP, Opal SM. Clinical trials of novel anticoagulants for severe sepsis: A tale of three molecules. Adv Sepsis 2004;4(1):17-23.

11.Padmanabhan R, LaRosa SP, Tomecki KJ. What’s new in antibiotics? Dermatol Clin 2005; 23(2):301-312.

12.LaRosa SP, Opal SM. Tissue factor pathway inhibitor and antithrombin trial results. Crit Care Clin 2005; 21:433-448.

13.Choure AJ, Shrestha RK, LaRosa SP, et al. Fever, chills, and chest radiographic infiltrates in a middle-aged woman. Cleve Clin J Med 2005;72 (5):367-374.

14.LaRosa, SP. Use of corticosteroids in the sepsis syndrome: What do we know now? Cleve Clin J Med 2005;72(12):1121-1127.

15.LaRosa SP, Opal SM, Utterback B, et al. Decreased protein C, protein S and antithrombin levels are predictive of poor outcome in gram-negative sepsis caused by Burkholderia pseudomallei. Int J Infect Dis 2006;10(1):25-31.

16.LaRosa SP. Drotrecogin alfa (activated) in severe sepsis.[comment]. N Engl J Med 2006; 354(1):94-96; author reply 94-96, 2006 Jan 5

17.Soliman MM, Dorotta I, LaRosa SP, et al. A case of undiagnosed syphilis in a patient undergoing coronary artery bypass graft and aortic valve surgery. Infect Dis Clin Pract 2008;16(1):76-78.

18.LaRosa SP, Opal SM. Sepsis strategies in development. Clin Chest Med 2008;29(4):735-747.

19.Holubar, M. Connor, M. LaRosa, SP, Singh A. Diagnostic dilemma: The heart of the matter. Am J Med. 2009; 122 (4):335-337.

20.Laterre PF, Opal SM, Abraham E, LaRosa SP, Creasey AA, Xie F, Poole L, Wunderink RG. A clinical evaluation committee assessment of recombinant human tissue factor pathway inhibitor (Tifacogin) in patients with severe community-acquired pneumonia. Critical Care 2009;13(2):R36.

21.Opal SM, LaRosa SP. Year in Review 2008: Critical care sepsis. Critical Care 2009;13:224.

22.Tidswell M, Tillis W, LaRosa SP, et al. Phase 2 trial of eritoran tetrasodium (E5564), a TLR4 antagonist, in patients with severe sepsis. Crit Care Med 2010;38(1):72-83.

23.Chan PA, Connell NT, Gabonay AM, Westley B, Larkin JM, LaRosa SP, et al. Oseltamivir resistant 2009-2010 pandemic influenza A (H1N1) in an immunocompromised patient. Clin Microbiol Infect 2010;16(10):1576-1578.

24.LaRosa SP. Activated protein C for H1N1 influenza? More work to do! Crit Care 2010;14(3):156.

25.LaRosa SP, Opal SM. Sepsis Strategies – Old and New. Clin Invest 2011;1(2):195-210.

26.LaRosa SP, Opal SM. Biomarkers: The Future. Crit Care Clin 2011;27(2):407-419.

27.Wunderink RG, Laterre PF, François B, Perrotin D, Artigas A, Otero Vidal L, Lobo SM, San Juan J, Hwang SC, Dugernier T, LaRosa S, et al. Recombinant Tissue Factor Pathway Inhibitor in Severe Community-Acquired Pneumonia: A Randomized Trial. Am. J. Respir. Crit. Care Med 2011 Jun 1;183(11):1561-1568.

28.Tidswell M, LaRosa SP. Toll-like receptor-4 antagonist eritoran tetrasodium for severe sepsis. Expert Rev Anti Infect Ther. 2011;9(5):507-20.

29.Kalil AC, LaRosa SP, Gogate J, Lynn M, Opal SM; the Eritoran Sepsis Study Group. Therapies for Severe Sepsis. Influence of Severity of Illness on the Effects of Eritoran Tetrasodium (E5564) and on Other Therapies for Severe Sepsis. Shock. 2011;36(4):327-31.

30.Kalil AC, LaRosa SP. Real-Life Experience with Drotrecogin Alfa (Activated) for Severe Sepsis: An Effectiveness and Safety Meta-analysis and Meta-regression. Lancet ID 2012;12(9):678-86

31.LaRosa SP, Opal SM. Immune Aspects of Sepsis and Hopes for new therapeutics. Curr Infect Dis Rep. 2012;14(5):474-83.

32.White paper: recommendations on the conduct of superiority and organism-specific clinical trials of antibacterial agents for the treatment of infections caused by drug-resistant bacterial pathogens. Infectious Diseases Society of America. Clin Infect Dis. 2012;55(8):1031-46

33.Ranganath S, McGhie TA, LaRosa S, Lehman W, Fader R. Clinical and Laboratory Diagnosis of Central Nervous System Histoplasmosis. Am J Med 2012; 125 (10):e1-e2.

34.Opal SM, Laterre PF, Francois B, LaRosa SP, et al. A Controlled Clinical Trial of Eritoran, an Antagonist of MD2-TLR4, in Patients with Severe Sepsis: THE ACCESS TRIAL. JAMA 2013;301 (11): 1154-1162

35.Vincent JL, Ramesh M, Ernest D, LaRosa SP. A Randomized, Double-Blind, Placebo-Controlled, Phase-2B Study to Evaluate the Safety and Efficacy of Recombinant Human Soluble Thrombomodulin, ART-123, in Patients with Sepsis and Suspected Disseminated Intravascular Coagulation. Crit Care Med. 2013;41(9):2069-2079.

36.Opal SM, LaRosa SP. Recombinant Human Activated Protein C as a Therapy for Severe Sepsis: Lessons Learned? Am J Respir Crit Care Med. 2013;187(10):1041-3.

37.Bernard GR, Francois B, Mira JP,Vincent JL, Dellinger RP, Russell JA, LaRosa SP, et al. Evaluating the efficacy and safety of two doses of the polyclonal anti-TNF-α fragment antibody AZD9773 in adult patients with severe sepsis and/or septic shock: randomized, double-blind, placebo-controlled Phase IIb study. Crit Care Med 2014;42 (3):504-511.

38.McKrea K, Ward R, LaRosa SP. Removal of Carbapenem-Resistant Enterobacteriaceae (CRE) from Blood by Heparin-Functional Hemoperfusion Media. PLoS One 2014; 9 (12): e114242. doi:10.1371/journal.pone.0114242

39.Yende S, Austin S, Rhodes A, Finfer S, Opal S, Thompson T, Bozza FA, LaRosa SP, Ranieri M, Angus D. Long-term quality of life among survivors of severe sepsis: analyses of two international trials. Crit Care Med 2016 Mar 17

BOOKS AND BOOK CHAPTERS

1.Tabbarah K, Choueiri T, Tachopoulou O, LaRosa S. 59 year old diabetic man with a painful hand ulcer. In: Longworth DL, Stoller JK, Casey DM, Jewell JK, Eds. Cleveland Clinic Internal Medicine Case Reviews. Philadelphia: Lippincott, Williams and Wilkins, 2003:166-169.

2.LaRosa SP, Opal SM. Sepsis. Scientific American Textbook of Medicine. (online) 7/2014 http://www.sciammedicine.com/sciammedicine/institutional/tableOfContent.action#

3. Opal SM, LaRosa SP. The future of diagnosis and treatment for sepsis. Mexican Critical Care Association 2008 (in press).

ABSTRACTS

1.LaRosa S, Gordon S, Kalmadi S, Truesdell L, Avery R, Arroliga A, Longworth D.

Should Prophylaxis for Pneumocystis carinii Pneumonia in Solid Organ Transplant Ever Be Discontinued? 34th Annual Meeting of the Infectious Diseases Society of America, September 18-20, 1996, New Orleans, LA. Clin Infect Dis 1996;23(4):902. [Abstract #230]

2.LaRosa S, Kalmadi S, Longworth D, Truesdell L, Fisher C, Cornish N, Gordon S. Pneumocystis carinii Pneumonia in Patients without AIDS. 34th Annual Meeting of the Infectious Diseases Society of America, September 18-20, 1996, New Orleans, LA. Clin Infect Dis 1996; 23(4):902 [Abstract #229].

3.LaRosa S, Kalmadi S, Longworth D, Truesdell L, Fisher C, Cornish N, Gordon S. Pneumocystis carinii Pneumonia in Patients without AIDS. 35th Annual Meeting of the Infectious Diseases Society of America, September 18-20, 1997, San Francisco, CA. Clin Infect Dis 1997; 25:473 [Abstract #640].

4.Smith K, LaRosa S, Neal J, Winton E, Fisher C. Purpura Fulminans and S.

Pneumoniae Sepsis with Severe Acquired Protein C Deficiency Successfully Treated with Recombinant Human Activated Protein C. XVII Congress of the Intl. Society on Thrombosis and Haemostasis, Washington, DC, August 1999.

5.LaRosa SP, Opal SM, Utterback B, Yan B, Helterbrand J, Simpson AJ, White N, Fisher CJ. Decreased Protein C, Protein S and Antithrombin III Levels are Predictive of Poor Outcome in Gram-negative Sepsis caused by Burkholderia pseudomallei. Crit Care 2000;4(suppl. 1): S18.

6.LaRosa SP, Vincent JL, Bellomo R, et al. Baseline Characteristics of Patients enrolled in the Phase III trial of rhAPC in Severe Sepsis. The Society of Critical Care Medicine’s 30th Critical Care Congress, February, 2001.

7.Bernard GR, Laterre PF, LaRosa SP, et al. The Efficacy and safety of Recombinant Human Activated Protein C for the Treatment of Patients with Severe Sepsis. The Society of Critical Care Medicine’s 30th Critical Care Congress, February 2001.

8.Dhainaut JF, LaRosa SP, Fisher CJ, Yan SB, Bernard GR for the PROWESS Study Group Effect of Baseline Protein C, Antithrombin and IL-6 Levels on the Mortality Reduction Associated with Recombinant Human Activated Protein C in Patients with Severe Sepsis. American Thoracic Society International Conference, San Francisco, CA, May 18-23, 2001.

9.Ely EW, LaRosa SP, Helterbrand JD, Bernard GR for the PROWESS Study Group Effect of Age on the Mortality Reduction Associated with Recombinant Human Activated Protein C in Patients with Severe Sepsis. American Thoracic Society International Conference, San Francisco, CA, May 18-23, 2001.

10.LaRosa SP, Basson B, Dhainaut JF, Kimasewitz G, Opal SM, Drotrecogin Alfa (Activated) Reduces Mortality in Patients with Severe Sepsis Irrespective of Bacterial Pathogen Classification. 41st International Conference on Antimicrobial Agents and Chemotherapy, Chicago, IL, December 2001.

11.Garber GE, Opal SM, LaRosa SP, and Maki DG. Fungal Infections as an Important Cause of Severe Sepsis. Focus on Fungal Infections 13, Maui, Hawaii, March 19-21, 2003.

12.LaRosa SP, Starkey C, Yen-Lieberman B, Annane D, Bellisant E. A pilot study to examine the presence of Cytomegalovirus viremia and its relationship with adrenal function in patients with acute refractory septic shock. Crit Care Med 2003;31(12)suppl:A119

13.Opal S, Wunderink R, Laterre PF, LaRosa S, Creasey AA, Tobias J. Therapeutic Rationale for Tissue Factor Pathway Inhibitor (TFPI) for Severe Community Acquired Pneumonia CAP). 42nd Annual Meeting of the Infectious Diseases Society of America, Boston, MA, September 30-October 3, 2004.

14.Opal S, Laterre PF, Wunderink R, LaRosa S, Su G, Hua, Y, Mendelson M. Serum Procalcitonin and Prothrombin Fragment 1.2 in Severe CAP: Can Biomarkers Predict Survival Benefit in Tifacogin Patients? 48th Annual Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC)/46th Annual Meeting the Infectious Diseases Society of America, Washington, DC, October 25-28, 2008.

15.Kalil AC, LaRosa SP. Real-Life Experience with Drotrecogin Alfa Activated for Severe Sepsis: An Effectiveness and Safety Meta-analysis. 40th Critical Care Congress, San Diego, CA, January 15-19, 2011. [Abstract 424].

16.LaRosa SP, Tidswell MA. Comparative Efficacy of Eritoran, a Toll-Like Receptor 4 Antagonist, in Patients with Severe Sepsis and Higher Risk of Mortality by Type of Causative Pathogen. 40th Critical Care Congress, San Diego, CA, January 15-19, 2011. [Abstract 428].

17.LaRosa SP, McCrea K, Ward R. Removal of Cytomegalovirus from blood by Heparin-functional Hemoperfusion Media. 44th Critical Care Congress, Phoenix, AZ, January 17-21, 2015. [Abstract 984].

INVITED PRESENTATIONS

1.“Protein C Replacement in Purpura Fulminans”. Emory University School of Medicine, Atlanta, GA, March, 1999

2.“Potential Use of Activated Protein C as a treatment modality for Microvascular Coagulopathy". DIC Subcommittee, International Society on Thrombosis and Hemostasis, Washington, DC, August, 1999

3."The Journey from Academia to Industry and Back Again". Clinical Investigator Training Program, Harvard- MIT Division of Health and Technology, Boston, MA, February, 2000

4."Clinical Trials in Sepsis: Historical Lessons and Novel Approaches". Infectious Disease Grand Rounds, Cleveland Clinic Foundation, Cleveland, OH, June, 2000

5."Endothelial and Coagulation Dysfunction in Sepsis/MODS". Organ Failure 2000, New York, NY, September, 2000

6."Therapeutic Innovations and Controversies in Microcirculatory Dysfunction". Organ Failure 2000, New York, NY, September, 2000

7."Baseline Characteristics of Patients enrolled in the Phase III trial of rhAPC in Severe Sepsis". Society of Critical Care Medicine, San Francisco, CA, February, 2001

8.“Drotrecogin Alfa (Activated) Reduces Mortality in Patients with Severe Sepsis Irrespective of Bacterial Pathogen Classification”. Chicago, IL, December, 2001

9.“Antibiotics- What’s New”. May Day Therapy-Dermatology, Cleveland, OH. May, 2002

10.“Sepsis- The Evolving Picture”. Chapman Critical Care Symposium, Akron, OH, May, 2002

11.“Sepsis”, Combined Medical/Surgical Challenges, Fairview Hospital, Cleveland, OH, November, 2002

12.“Approach to the Septic Patient”. Infectious Diseases: A Course for Practicing Clinicians, Cleveland, OH, June 2003.

13.“Current Management of Severe Sepsis and Septic Shock”. Grand Rounds: Infectious Disease Update, The Warren Alpert Medical School of Brown University, Department of Medicine, Providence, RI, April 12, 2005.

14."A 58-year-old man with chest pain radiation to his back and new onset lower extremity weakness". Grand Rounds: M&M, The Warren Alpert Medical School of Brown University, Department of Medicine, Providence, RI, July 12, 2005.

15.“anti-TNF Therapy for Sepsis. Is the Story Over?”. TNF Summit, Cleveland, OH,

August, 2005

16.“Infections Related to Trauma”. Infectious Diseases Fellowship Lecture Series, The Warren Alpert Medical School of Brown University, Providence, RI, February 17, 2006.

17."An 88-year-old man with CMML who presents with progressive weakness and fatigue". Grand Rounds: M&M, The Warren Alpert Medical School of Brown University, Department of Medicine, Providence, RI, February 7, 2006.

18."TNF as a specific target in severe sepsis - Is the story over". Grand Rounds: The Warren Alpert Medical School of Brown University, Division of Infectious Diseases, Providence, RI, November 29, 2006.

19."A 56-year-old man with fever and recent travel". Grand Rounds: M&M, The Warren Alpert Medical School of Brown University, Department of Medicine, Providence, RI, January 23, 2007.

20.“A 66-year-old man with six weeks of increasing abdominal girth”. Grand Rounds: M&M, The Warren Alpert Medical School of Brown University, Department of Medicine, Providence, RI, March 13, 2007.

21.“A 52-year-old man with fevers and chills”. Grand Rounds: M&M, The Warren Alpert Medical School of Brown University, Department of Medicine, Providence, RI, April 10, 2007.

22.“Purpura Fulminans”. Grand Rounds: Cleveland Clinic Foundation, Division of Infectious Diseases/Vascular Medicine, Cleveland, OH, April 11, 2007.

23.“Sepsis, Severe Sepsis, and Septic Shock”. American Academy for Clinical Laboratory Science-Central New England (ASCLS-CNE) 58th Annual Clinical Laboratory Science Convention, Microbiology Section, Providence, RI, May 9, 2007.

24.“Antibiotic Issues in the ICU”. 2008 Update in Critical Care: Implementing Bedside Practice. Rhode Island Hospital and the Miriam Hospital Division of Critical Care Medicine, Providence, RI, June 6, 2008.

25."Procalcitonin". Grand Rounds: The Warren Alpert Medical School of Brown University, Division of Infectious Diseases, Providence, RI, September 25, 2008.

26.“C. Difficile”. 2009 Update in Critical Care: Where are we now and where are we going? Rhode Island Hospital and the Miriam Hospital Division of Critical Care Medicine, Providence, RI, April 17, 2009.

27.“Sepsis and Septic Shock.” MTC 501, Advanced Clinical Microbiology. University of Rhode Island, Providence, RI, September 16, 2009.

28.“A 44-year-old woman with abdominal pain and lower extremity rash.” Grand Rounds Panelist: M&M, The Warren Alpert Medical School of Brown University, Department of Medicine, Providence, RI, September 22, 2009.

29.“Sepsis”. Noon Conference Lecture: The Warren Alpert Medical School of Brown University, Department of Medicine, Providence, Rhode Island, February 2010.

30.“Biomarkers for Sepsis”. 14th International Congress on Infectious Diseases (ICID), Miami, FL, March 9-12, 2010.

31.“Sepsis and Septic Shock”. Grand Rounds: Rhode Island Hospital, Department of Pathology, Providence, RI, May 11, 2010.

32.”A 51-year-old female presents with fever and generalized fatigue.” Grand Rounds Panelist: M&M, The Warren Alpert Medical School of Brown University, Department of Medicine, Providence, RI, November 2, 2010.

33.“Antithrombotics for Sepsis”. Society of Critical Care Medicine (SCCM) 40th Critical Care Congress, San Diego, CA, January 18, 2011

34.“Biomarkers for Sepsis: From Readily to Experimental”. Grand Rounds: The Warren Alpert Medical School of Brown University, Division of Infectious Diseases, Providence, RI, January 20, 2011.

35.“The Sepsis Disease State”. Medical Grand Rounds, Scott and White Healthcare, Temple, TX, August 5, 2011

36.“The Future of Sepsis Clinical Research”, Snyder Institute of Infection, Immunity and Inflammation Research Conference, Calgary, Canada, September 5, 2011.

37.“ACCESS Trial Results”. Society of Critical Care Medicine (SCCM) 41th Critical Care Congress, Houston, TX, February 6,2012

38.“Procalcitonin: Pro/Con Debate”. Texas Infectious Disease Society Meeting, San Antonio, TX, June 9th, 2012.

39.“Severe Sepsis”, Medical Grand Rounds, Beverly Hospital, Beverly, MA, September 30th, 2013

40.“A General Review of Procalcitonin and Utilization in De-escalating Antibiotics”, Fatima Hospital, North Providence, RI, February 6, 2014.

GRANTS

1.Clinical Coordinating Center for TFP008: Phase III, Multicenter, Randomized, Placebo-Controlled, Double-Blind, Three-Arm Study to Evaluate the Safety and Efficacy of Tifacogin (Recombinant Tissue Factor Pathway Inhibitor) Administration in Subjects with Severe Community Acquired Pneumonia. Project No. 6057; Sponsor: (originally Chiron Corp) Novartis Pharmaceuticals; Amount: $1,419.136; Term: April 1, 2004 to July 28, 2008; Co-investigator: Steven LaRosa, M.D.

2.Clinical Coordinating Center for E5564-G000-301: ACCESS: A Controlled Comparison of Eritoran Tetrasodium and Placebo in Patients with Severe Sepsis. Project No. 7051; Sponsor: Eisai Medical Research Inc.; Amount: $4,033,397; Term: December 2005 to January 31, 2011; Principal Investigator: Steven LaRosa, M.D

3.Clinical Coordinating Center for LF-0801: A Phase 2 Randomized, Double-blind, Placebo-controlled Study of the Safety and Efficacy of Talactoferrin Alfa in Patients with Severe Sepsis. Project 8905; Sponsor: Agennix Incorporated; Amount: $156,200; Term: March 1, 2008 to July 2009; Principal Investigator: Steven LaRosa, M.D.

4.Clinical Coordinating Center for A Multicenter, Randomised, Double-Blind, Placebo-controlled Phase IIb Study to Compare the Efficacy and Safety of Two or Three Dosing Regimens of Intravenous Infusions of CytoFab™ (AZD9773) in Adult Patients with Severe Sepsis. Project No. 9575; Sponsor: AstraZeneca Pharmaceuticals LP; Amount: $653,764; Term: November 1, 2009 to May 31, 2011; Principal Investigator: Steven LaRosa, M.D.

5.Clinical Coordinating Center for OASIS: A Phase 2/3 Randomized, Double-Blind, Placebo-Controlled Study of the Safety and Efficacy of Talactoferrin Alfa in Patients with Severe Sepsis. Protocol No. LF-0802; Sponsor: Agennix Incorporated; Amount: $1,558,017; Term: November 2010 to May 31, 2011; Principal Investigator: Steven LaRosa, M.D.

Contact this candidate